What are the recommended induction and maintenance doses of Valcyte (valganciclovir) for symptomatic cytomegalovirus disease in immunocompromised adults, including renal dose adjustments, monitoring parameters, and alternative therapies?

Valganciclovir (Valcyte) for CMV Disease in Immunocompromised Adults

For symptomatic CMV disease in immunocompromised adults, administer valganciclovir 900 mg orally twice daily for 14–21 days as induction therapy, followed by 900 mg once daily for lifelong maintenance therapy, with mandatory dose reductions based on creatinine clearance and twice-weekly CBC monitoring during induction. 1, 2

Induction Therapy Dosing

Standard Regimen

• Valganciclovir 900 mg orally twice daily for 14–21 days is the recommended induction dose for CMV retinitis and other end-organ disease in adults 2
• This oral regimen provides systemic ganciclovir exposure equivalent to intravenous ganciclovir 5 mg/kg twice daily 3, 4
• The 14–21 day duration is required to achieve adequate viral suppression; do not shorten below 14 days as this increases risk of early progression 1

When to Use IV Ganciclovir Instead

• Sight-threatening lesions (adjacent to optic nerve or fovea) require combination IV therapy: ganciclovir 5 mg/kg every 12 hours PLUS foscarnet 60 mg/kg every 8 hours for 14–21 days 1
• Severe gastrointestinal symptoms that impair oral absorption mandate IV ganciclovir 5 mg/kg every 12 hours 1
• CMV encephalitis requires IV ganciclovir 5 mg/kg every 12 hours for 2–3 weeks, though monotherapy often fails and combination with foscarnet should be strongly considered 1, 5

Maintenance (Suppressive) Therapy

Lifelong Suppression Required

• Valganciclovir 900 mg once daily indefinitely after completing induction 2
• Current antivirals do not cure CMV disease; chronic suppressive therapy must continue for life unless immune reconstitution occurs 6, 1
• Do not discontinue maintenance therapy even when disease appears stable—cessation leads to rapid progression 1

Exception: Immune Reconstitution

• Discontinuation may be considered only if CD4+ count rises to >100–150 cells/µL and remains sustained for ≥3–6 months on antiretroviral therapy 6
• This decision requires consultation with an ophthalmologist and continued monthly ophthalmologic monitoring 6

Renal Dose Adjustments (Critical)

Valganciclovir Maintenance Dosing by Creatinine Clearance

CrCl (mL/min)	Maintenance Dose
≥60	900 mg once daily
40–59	450 mg once daily
25–39	450 mg every 48 hours
10–24	450 mg twice weekly
<10 or dialysis	Not recommended

1

• Failure to adjust for renal function is a common pitfall that leads to severe toxicity 1
• Measure serum creatinine at baseline and at least weekly during induction 1

Mandatory Monitoring Parameters

Hematologic Surveillance

• Complete blood count and platelets twice weekly during induction and once weekly during maintenance 1, 2
• Myelosuppression (neutropenia, anemia, thrombocytopenia) is the major dose-limiting toxicity, affecting up to 40% of patients 1, 2
• Dose reduction or interruption may be necessary; consider granulocyte colony-stimulating factor for severe neutropenia 1

Ophthalmologic Monitoring (for Retinitis)

• Dilated indirect ophthalmoscopy required at diagnosis, after induction, at 1 month, then monthly while on therapy 1
• Patients should assess visual acuity regularly (e.g., reading newsprint) and report increased floaters immediately 6

Renal Function

• Monitor serum creatinine regularly; rising values signal nephrotoxicity requiring dose modification 1, 2
• Maintain adequate hydration and avoid concomitant nephrotoxic drugs 1

Alternative and Combination Therapies

For Treatment Failure or Resistance

• Combination therapy: ganciclovir 5 mg/kg IV every 12 hours PLUS foscarnet 60 mg/kg IV every 8 hours for 3 weeks achieves improvement in 74% of cases 1, 5
• Long-term ganciclovir therapy can select for resistant CMV strains (IC₅₀ >3 µg/mL); switch to foscarnet or combination therapy when resistance is suspected 1

Alternative Agents

• Foscarnet is the primary alternative for patients who cannot tolerate valganciclovir due to neutropenia or thrombocytopenia 2
• Cidofovir (parenteral) is another option for chronic suppression 6
• Maribavir shows promise for refractory or resistant infections 2

Local Therapy for Retinitis

• Ganciclovir intraocular implant plus oral valganciclovir is effective for retinitis but does not protect the contralateral eye or other organs 6
• Intraocular therapy alone is insufficient; systemic therapy reduces morbidity in the contralateral eye 6

Special Populations and Contraindications

Hepatic Dysfunction

• Valganciclovir should not be used in liver transplant patients with hepatic dysfunction due to higher rates of CMV disease compared to IV ganciclovir 2
• One study showed valganciclovir prophylaxis failed in 14.3% of liver transplant recipients, with 26% failure in the high-risk group 7

Hematopoietic Stem Cell Transplant

• Valganciclovir is acceptable for pre-emptive therapy in allogeneic HCT recipients in the absence of substantial gastrointestinal graft-versus-host disease 2

Common Pitfalls to Avoid

• Never use valacyclovir for CMV prophylaxis—it showed an unexplained trend toward increased mortality in AIDS patients 6
• Never use acyclovir for CMV disease—it is not effective 6
• Do not use oral ganciclovir for maintenance—valganciclovir provides superior bioavailability (60% vs. 6%) and reduces risk of viral resistance 3, 8
• Avoid rapid infusion if using IV ganciclovir—each dose must be infused over 1–2 hours to prevent acute toxicity and neuromuscular blockade 1

Cost and Convenience Considerations

• Valganciclovir offers significant advantages over IV ganciclovir: avoids catheter-related complications, improves compliance with once-daily maintenance dosing, and provides potential cost savings 3, 9
• The simple oral regimen is preferred for peripheral retinal lesions that are not immediately sight-threatening 1